DK148595B - Analogifremgangsmaade til fremstilling af s,s'-bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)carbonodithioat eller pharmaceutiskacceptable salte deraf - Google Patents
Analogifremgangsmaade til fremstilling af s,s'-bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)carbonodithioat eller pharmaceutiskacceptable salte deraf Download PDFInfo
- Publication number
- DK148595B DK148595B DK303274AA DK303274A DK148595B DK 148595 B DK148595 B DK 148595B DK 303274A A DK303274A A DK 303274AA DK 303274 A DK303274 A DK 303274A DK 148595 B DK148595 B DK 148595B
- Authority
- DK
- Denmark
- Prior art keywords
- hydroxy
- bis
- methyl
- hydroxymethyl
- pyridylmethyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 6
- 150000003839 salts Chemical class 0.000 title claims description 5
- 238000000034 method Methods 0.000 title claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- -1 (3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl) carbonate Chemical compound 0.000 claims description 6
- PZTHSDYEYQLIDM-UHFFFAOYSA-N 4-methoxy-2-methyl-5-methylsulfanylpyridin-3-ol Chemical compound COC1=C(O)C(C)=NC=C1SC PZTHSDYEYQLIDM-UHFFFAOYSA-N 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 206010015150 Erythema Diseases 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- SKOLWUPSYHWYAM-UHFFFAOYSA-L methanethioate Chemical compound [O-]C([S-])=S SKOLWUPSYHWYAM-UHFFFAOYSA-L 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 21
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- LXRYFIYUNMEPLC-UHFFFAOYSA-N (2,2,8-trimethyl-4h-[1,3]dioxino[4,5-c]pyridin-5-yl)methanethiol Chemical compound C1OC(C)(C)OC2=C1C(CS)=CN=C2C LXRYFIYUNMEPLC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 206010003591 Ataxia Diseases 0.000 description 3
- 206010006102 Bradypnoea Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000024336 bradypnea Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- QWAMVVAYJIUJMX-UHFFFAOYSA-N CC1(C)OC2=C(C)N=CC(COC(S)=S)=C2CO1 Chemical compound CC1(C)OC2=C(C)N=CC(COC(S)=S)=C2CO1 QWAMVVAYJIUJMX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 230000003356 anti-rheumatic effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 229910017604 nitric acid Inorganic materials 0.000 description 2
- 201000003068 rheumatic fever Diseases 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- HVPZELCZNCVMBD-UHFFFAOYSA-N (4-nitrophenoxy)methanethioic s-acid Chemical compound [O-][N+](=O)C1=CC=C(OC(S)=O)C=C1 HVPZELCZNCVMBD-UHFFFAOYSA-N 0.000 description 1
- TTWWZVGVBRPHLE-UHFFFAOYSA-N 1,1-dichloro-n-phenylmethanimine Chemical compound ClC(Cl)=NC1=CC=CC=C1 TTWWZVGVBRPHLE-UHFFFAOYSA-N 0.000 description 1
- BGPJLYIFDLICMR-UHFFFAOYSA-N 1,4,2,3-dioxadithiolan-5-one Chemical compound O=C1OSSO1 BGPJLYIFDLICMR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- JXYDRIBYAKJTIW-UHFFFAOYSA-N 4-(hydroxymethyl)-2-methyl-5-(sulfanylmethyl)pyridin-3-ol Chemical compound CC1=NC=C(CS)C(CO)=C1O JXYDRIBYAKJTIW-UHFFFAOYSA-N 0.000 description 1
- YPRMPUCBNRXSEU-UHFFFAOYSA-N 4-(hydroxymethyl)-2-methyl-5-(sulfanylmethyl)pyridin-3-ol;hydrochloride Chemical compound Cl.CC1=NC=C(CS)C(CO)=C1O YPRMPUCBNRXSEU-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022061 Injection site erythema Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MWZFMJHQNFXPAA-UHFFFAOYSA-N O.Cl.Cl.C(OCC=1C(=C(C(=NC1)C)O)CO)(=S)S Chemical compound O.Cl.Cl.C(OCC=1C(=C(C(=NC1)C)O)CO)(=S)S MWZFMJHQNFXPAA-UHFFFAOYSA-N 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical class [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- OFIHJYLASXZYAR-UHFFFAOYSA-N [Hg](=O)=O Chemical compound [Hg](=O)=O OFIHJYLASXZYAR-UHFFFAOYSA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- YNNGZCVDIREDDK-UHFFFAOYSA-N aminocarbamodithioic acid Chemical compound NNC(S)=S YNNGZCVDIREDDK-UHFFFAOYSA-N 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000003435 antirheumatic agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 229960003675 diethadione Drugs 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- ROORDVPLFPIABK-UHFFFAOYSA-N diphenyl carbonate Chemical compound C=1C=CC=CC=1OC(=O)OC1=CC=CC=C1 ROORDVPLFPIABK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- QMEZUZOCLYUADC-UHFFFAOYSA-N hydrate;dihydrochloride Chemical compound O.Cl.Cl QMEZUZOCLYUADC-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940101209 mercuric oxide Drugs 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- SJIIDWBFRZACDQ-UHFFFAOYSA-N pyridin-2-ylmethanethiol Chemical compound SCC1=CC=CC=N1 SJIIDWBFRZACDQ-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- UOULCEYHQNCFFH-UHFFFAOYSA-M sodium;hydroxymethanesulfonate Chemical compound [Na+].OCS([O-])(=O)=O UOULCEYHQNCFFH-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
- C07D213/66—One oxygen atom attached in position 3 or 5 having in position 3 an oxygen atom and in each of the positions 4 and 5 a carbon atom bound to an oxygen, sulphur, or nitrogen atom, e.g. pyridoxal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/26—Radicals substituted by halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
- C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
i 148595
Den foreliggende opfindelse angår en analogifremgangsmåde til fremstilling af det hidtil ukendte S,S'-bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)carbonodithioat eller pharmaceutisk acceptable salte deraf, hvilken frem-5 gangsmåde er ejendommelig ved det i kravets kendetegnende del anførte. De omhandlede forbindelser egner sig som lægemidler, især til behandling af rheumatisk arthritis.
Den ved fremgangsmåden ifølge opfindelsen fremstillede 10 forbindelse har den i kravet angivne almene formel I.
Opfindelsen angår som nævnt også fremstilling af pharmaceutisk acceptable salte, nemlig additionssalte af mineralsyrer og organiske syrer af sædvanlig art, såsom saltsyre, hydrogenbromidsyre, svovlsyre, salpetersyre, malein-15 syre, fumarsyre, vinsyre og ravsyre.
Til trods for en intensiv forskning i de sidste 20 år i forbindelse med antiinflammatoriske midler er der stadig et stort behov for et effektivt og uskadeligt middel til behandling af rheumatisk arthritis. Konventionelle ikke-20 steroide, antiinflammatorisk, analgetisk og antipyretisk aktive midler, såsom aspirin og mange eksperimentelt nye lægemidler under klinisk bedømmelse, er effektive til fjernelse af symptomer på det akutte syndrom, men er ude af stand til at indvirke på selve sygdommens forløb. Som føl-25 ge heraf har den antirheumatiske virkning af to gamle mid ler, nemlig guld og D-penicillamin, til trods for deres potentielle sidevirkninger, opnået fornyet interesse i de sidste få år. Den kliniske effektivitet af begge lægemidler er atter blevet bekræftet af godt kontrollerede undersøgelser på en række klinikker. Mange gigtforskere har ud-30 trykt den opfattelse, at en D-penicillamin-lignende for bindelse med forbedrede egenskaber ville være et værdifuldt bidrag til medicinen på dette vigtige felt. Det må derfor betragtes som en vigtig opdagelse, at den hidtil ukendte 148595 2 mercaptomethylpyridin, der omfattes af den foreliggende opfindelse, har en betydelig grad af antirheumatisk arthri-tis-aktivitet.
De omhandlede forbindelser kan indgives oralt, topisk, pa-5 renteralt, ved inhalering af spray eller rektalt i enheds-doser indeholdende konventionelle, ikke-giftige, pharmaceu-tisk acceptable bæremedier, tilsætningsmidler og fyldstoffer.
Sædvanligvis er en effektiv dosis på 5-50 mg pr. kg legems-10 vægt pr. dag.
Forbindelsen I fremstilles ifølge opfindelsen ved (å) behandling af 2-methyl-3-hydroxy-4-hydroxymethyl-5-mercapto-methylpyridin med p-nitrophenylchlorformiat eller phosgen i et aprotisk opløsningsmiddel, såsom 15 THF, ether, glyme eller diglyme, ved 0-1 °C i 1-3 ti mer efterfulgt af opvarmning til 20-50 °C.
(b) hydrolyse af en forbindelse med formlen: r.1och2 r17 cii2or1 I c„ ς 1 os'!9 L y XX 11 S^CH3 med fortyndet base eller med fortyndet mineralsyre ved 19 ?n 20-50 °C i 1-5 timer, hvor R·1 og er ens eller for- skellige og repræsenterer hydrogen, en syrelabil be- 3 148595 = 19
skyttende gruppe, såsom tetrahydropyranyl, eller R
20 og R repræsenterer tilsammen en gruppe med formlen:
/G
4 s hvor R og R er ens eller forskellige og er hydrogen, 17 l o C, ,-alkyl eller phenyl, og R er =0 eller =N-R , t g hvor R er hydrogen, phenyl eller C, ,-alkyl, idet, 17 19 20 når R er =0, må R og R ikke begge være hydrogen; (c) oxidation af en forbindelse med formlen:
^2°11 S C-HOII
II I
HO £Η,— S~ C — S —CH? JL OH III
n ti CBj'® CHj eller ch3 chYY S "lTCH3 1111 3 CH7-S-C-S-CH2-|r^^f vi,, med et oxidationsmiddel, såsom kaliumpermanganat, salpetersyre eller mercurioxid, ved stuetemperatur i 1-3 timer, om nødvendigt efterfulgt af hydrolyse af dioxin-gruppen; (d) syrehydrolyse af en forbindelse med formlen: 148595 4 CH2OR20
IV
CH3 N' med mineralsyre og langsom opvarmning til 80-100 °C, 19 20 hvor R og R* har den ovenfor angivne betydning.
EKSEMPEL 1 S,S *-bis(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylme-
Trin Ai Præparation af S,S'-bis(2,2,8-trimethyl-4H-l,3- dioxino-[4,5-c]pyridin-5-yl-methyl)-carbonodithioat
Til en isafkølet opløsning af 4,5 g 5-mercaptomethyl-2,2,8-trimethyl-l,3-dioxino[4,5-c]pyridin i 50 ml tør pyridin 10 dryppedes 10 ml af en 12,5¾ opløsning af phosgen i benzen.
Reaktionsblandingen bragtes op på stuetemperatur og omrør-tes i tre timer, hvorefter den blev inddampet i vakuum.
Remanensen ekstraheredes mellem benzen og mættet natrium-carbonatopløsning. Benzenlaget fraskiltes, vaskedes med 15 vand, tørredes over natriumsulfat og inddampedes i vakuum.
Remanensen kromatograferedes på 250 g silicagel. Ued elu-ering med ether dannedes 3,59 gS,S'-bis(2,2,8-trimethyl-4H-l,3-dioxino[4,5-c]pyridin-5-yl-methyl)-carbonodithioat, smp.: 88-9Q °C.
5 148595
Trin B; Præparation af S,S'-bis(3-hydroxy-4-hydroxymethyl- 2-methyl-5-pyridyl-methyl)carbonodithioat-dihydro-chlorid-monohydrat__
En opløsning af 0,2 g S,S'-bis(2,2,8-trimethyl-4H-l,3-dio-5 xino-[4,5-c]pyridin-5-yl-methyl-carbonodithioat i 0,9 ml iskold koncentreret saltsyre omrørtes i kulden i 5 minutter, hvorefter den fortyndedes til 2,5 ml med methanol.
Ved afkøling i is/acetone dannedes et krystallinsk bundfald, som frafiltreredes til dannelse af 0,120 g S,S'-bis(3-hy-10 droxy-4-hydroxymethyl-2-methyl-5-pyridy1-methyl)carbonodio- thioat-dihydrochlorid-monohydrat, smp.: 125-130 °C.
EKSEMPEL 2
Bis [2-methyl-3-hydroxy-4-hydroxymethylpyridyl-5-methylthio]- carbonat 15 En opløsning af 5-mercaptopyridoxin (0,1 mol) i tør tetra- hydrofuran (100 ml) omrøres ved 0-5 °C, medens 1-nitrophe-nylchlorformiat (0,1 mol) i tør tetrahydrofuran (10 ml) ledes ind i løbet af 1 time. Efter endnu 1 time inddampes opløsningen ved 10 °C til 10 ml. Om nødvendigt kan mellem-20 produktet p-nitrophenylmonothiocarbonat af 5-mercaptopyri- doxin isoleres ved filtrering på dette trin.
I stedet kan yderligere 0,1 mol 5-mercaptopyridoxin tilsættes forud for inddampning, og tetrahydrofuranopløsningen opvarmes til 40 °C. Efter inddampning ekstraheres dithio-25 carbonatet med ethylacetat (3 x 100 ml) fra mættet vandig natriumbicarbonat, og derefter tørres det organiske lag o-ver magnesiumsulfat. Det organiske lag filtreres og inddampes til tørhed. Det urene produkt kromatograferes på en kolonne af silicagel på 5 x 60 cm under anvendelse af op-30 løsninger af methylenchlorid-methanol som eluent, hvorved fås bis[2-methyl-3-hydroxy-4-hydroxymethyl]pyridyl-5-methyl-thio]carbonat i et udbytte på 7,3?ό og med et smeltepunkt på 175-181 °C.
6 148598 EKSEMPEL 3
Bis[2-methyl-3-hydroxy-4-hydroxymethylpyridyl-5-methylthio ]-carbonat
Til 0,05 mol ammoniumdithiocarbamat i 300 ml 75K ethanol 5 sættes 0,1 mol 5-chlormethyl-2,2,8-trimethyl-4H-M-dioxino- [4,5-e]pyridin (behandlet med HC1 + NaHCOj). Reaktionsblandingen koges under tilbagesvaling i 2 timer, afkøles til stuetemperatur, pg blandingen, som indeholder bis[2,2,8-trimethyl-4H-M-diox\no[4,5-c]pyridyl-5-methylthio]carbamat, 10 gøres sur med saltsyre. Efter tre timer ved stuetemperatur inddampes reaktionsblandingen, og remanensen optages med ether/benzen og overskud af mættet natriumbicarbonat. Det organiske lag fraskilles, vaskes grundigt med vand, tørres og inddampes til dannelse af bis[2-methyl-3-hydroxy-4-hy-15 drox‘ymethylpyridyl-5-methylthio]carbonat.
EKSEMPEL 4
Bis [2-methyl-3-hydroxy-4-hydroxymethylpyridy1-5-methylthio]-carbonat __ _ _ _______________________
Til 0,2 mol natriQmhydrid i tørt dimethylformamid under 20 nitrogen sættes under afkøling 0,2 mol 5-mercaptomethyl- 2,2,8-trimethyl-4H-M-dioxino[4,5-c]pyridin i dimethylformamid. Blandingen.omrøres i 15 minutter, efter at udviklin--gen af hydrogen er ophørt. Derpå tilsættes 0,1 mol phenyl-.isonitrildichlorid. Reaktionsblandingen omrøres ved stue-25 temperatur i 18 timer og inddampes derefter i vakuum. Remanensen, som indeholder bis[2,2,8-trimethyl-4H-M-dioxino-[4,5-c]pyridyl-5-methylthio]-N-phenylcarbamat, omrøres i 3 timer ved stuetemperatur i fortyndet saltsyre, l/ed behandling med mættet natriumbicarbonat fås derefter bis[2-30 methyl-3-hydroxy-4-hydroxymethylpyridyl-5-methylthio]car- bonat i et'udbytte på 83¾ og med et smeltepunkt på 174-176°C.
7 148595 EKSEMPEL 5
Bis [2-methyl-3-hydroxy-4-hydroxymethylpyridyl-5-methylthio]-carbonat
Til 0,1 mol natriummethoxid i 150 ml ethanol sættes 0,1 5 mol 5-mercaptomethyl-2,2,8-trimethyl-4H-M-dioxino[4,5-c]- pyridin. Efter 15 minutter fjernes ethanolen ved inddamp-ning i vakuum. Til det dannede natriummercaptid sættes 0,05 mol diphenylcarbonat, og den dannede masse opvarmes på dampbad i 1 time, hvorved der dannes bis[2,2,8-trimethyl-10 4H-M-dioxino[4,5-c]pyridyl-5-methylthio]carbonat. Efter afkøling til stuetemperatur tilsættes en blanding af benzen/ether og fortyndet natriumhydroxid. Det organiske lag fraskilles, vaskes grundigt med vand, tørres og inddampes, hvorved fås bis[2-methyl-3-hydroxy-4-hydroxymethylpyridyl-15 5-methylthiojcarbonat i et udbytte på 65?ό og med et smeltepunkt på 173-175 °C.
EKSEMPEL 6
Bis[2-methyl-3-hydroxy-4-hydroxymethylpyridy1-5-methylthio]-carbonat 1 2 3 4 5 6 7 8 9 10 11
Til 0,4 mol rødt mercurioxid, som suspenderes under kraf 2 tig omrøring i 200 ml vand, sættes 0,22 mol bis(2,2,8-tri- 3 methyl-4H-M-dioxino[4,5-c]pyridyl-5-methylthio)thiocarbo- 4 nat i 100 ml eddikesyreanhydrid. Reaktionsblandingen omrø 5 res ved stuetemperatur i 1 time og ekstraheres derefter 6 med ether/benzen (1:1). Det organiske lag fraskilles, vas 7 kes med mættet natriumbicarbonat-opløsning, vand og tørres 8 over natriumsulfat til dannelse af bis(2,2,8-trimethyl-4H- 9 M-dioxino[4,5-c]pyridyl-5-methylthio)-carbonat. Syrehydro 10 lyse under de sædvanlige betingelser giver bis[2-methyl-3- 11 hydroxy-4-hydroxymethylpyridyl-5-methylthio)carbonat i et udbytte på 20,2?ό og med et smeltepunkt på 1.7.4-176 °C.
148595 8 I stedet kan isopropylidengruppen hydrolyseres først efterfulgt af oxidation af thiocarbonatgruppen til carbo-natet til opnåelse af samme resultat.
EKSEMPEL 7 5 Bis[2-methyl-3-hydroxy-4-hydroxymethylpyridyl-5-methylthio]- carbonat
En blanding af 0,1 mol 2,2,8-trimethyl-4H-M-dioxino[4,5-c]~ pyridyl-5-methylthiocyanat og 5 ml svovlsyre opvarmes langsomt på dampbad. En kraftig udvikling af carbondioxid fin-10 der sted. Efter at gasudviklingen er ophørt, hældes reaktionsblandingen på is, og der omrøres i 3 timer ved stuetemperatur. Den dannede blanding hældes derefter i en blanding af ether/benzen og overskud af natriumbicarbonatopløs-ning. Det organiske lag fraskilles, vaskes grundigt med 15 vand, tørres og inddampes til dannelse af bis[2-methyl-3- hydroxy-4-hydroxymethylpyridyl-5-methylthiol]carbonat.
Pharmakoloqisk rapport
Oral toxicitet.
Toxiciteten blev bestemt på mus ved oral indgift i for-20 skellige doser og forskellige hjælpemidler, og LD^g blev bestemt eller skønnet. De opnåede resultater fremgår af følgende tabel.
Prøveforbindelse: S,S’-bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)carbonodithioat.
25 Hjælpemiddel: 1% vandig methylcellulose.
LD5Q > 6850 mg/kg, skønnet.
9 148595
Dosis Kone. Antal Antal Bemærkninger mg/kg % dyr døde 400 5 5 0 Ingen 600 5 5 0 900 5 5 0 1350 550 2025 550 3040 20 5 0 4560 20 5 0 6850 20 5 0
Prøveforbindelse: S, S ' -bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethy1)-carbonodithioat-dihydrochlorid.
Hjælpemiddel: vand.
LD^0 6910 (6080-7860) mg/kg, skønnet.
Dosis Kone. Antal Antal Bemærkninger mg/kg % dyr døde 5460 20 5 0 Efter omkring 10 minutters 7inn „n s , forløb blev der for alle koncentrationer iagttaget 9240 20 5 5 ataksi, bradypnea og klonisk ι?ηηη ?n c c konvulsion. Anden dag - ataksi, bradypnea og nedsat aktivitet. Død på 20 min, til 4 timer. En senere død på '5 til 6 dage.
Prøve forbindelse: S,S'-bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)-carbonodithioat-sulfat-|iemihydrat.
Hjælpemiddel: l?i vandig methylcellulose.
LD5q 8870 (7540-10400 mg/kg), skønnet,.
148595 ίο
Dosis Kone. Antal Antal Bemærkninger mg/kg % dyr døde 4450 20 5 0 Alle koncentrationer: bradypnea 4Λ7Π ?n S n °9 nedsat aktivitet. 10000 mg/kg: ataksi, skælven og klo- 5 10000 20 5 4 niske konvulsioner. Overlevende synes normale dagen efter lægemiddeladministrering. Død på 40 min. til 1,5 timer.
Prøveforbindelse: 5-mercaptopyridoxin-hydrochlorid.
Hjælpemiddel: vand ved pH 2,5.
Koncentration: 8SS.
LD^g: 1250 mg/kg; 95/i's fiducialgrænser 1060-1480 mg/kg.
Aktivitet for mercaptoalkylpyridinderivater i lymphokin-10 induceret inflammation i marsvin._
Grupper på fire marsvin blev doseret p.o. med en forbindelse på tidspunktet nul i en koncentration på 30 mg/kg eller 90 mg/kg. Hvert dyr modtog en anden dosis lægemiddel 17 timer senere. En time efter den anden dosis lægemiddel blev 15 hvert dyr intradermalt udsat for lymphokin, og størrelsen af erythema på injektionsstedet blev målt til tidspunktet 22 timer.
Resultater: Både sulfatet af S,S'-bis(3-hydroxy-4-hydroxy-methyl-2-methyl-5-pyridylmethyl)carbonothioat og dihydro-20 chloridet deraf udviste aktivitet sammenlignelig med akti viteten af 5-mercaptopyridoxin, men i en dosis på en tredjedel .
Claims (1)
148595 Dosis Erythema- Inhibering Aktivitet Behandling mg/kg diameter, % mm Saltvand - 11,1 5-mercaptopyridoxin 90 7,6 32 aktiv S,S'-bis(3-hydroxy-4-hydroxy- 30 7.2 36 aktiv carbonodithioat-dihydrochlo- rid S,S'-bis(3-hydroxy-4-hydroxymethyl-2-methyl- 5-pyridylmethyl)carbono- 30 7,5 34* aktiv dithioat-sulfat-hemihy- drat * statistisk signifikans P 0,05 Patentkrav : Analogifremgangsmåde til fremstilling af S,S'-bis-(3-hy-droxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)carbonodi-thioat med formlen: ch2oh O CH-OH I il I HOyyB2"s_ c_ s_ch2y\/oh τ CH^^N ' ^ N CH3 eller pharmaceutisk acceptable salte deraf, 148595 kendetegnet ved, a) at 5-mercaptopyridoxin behandles med p-nitrophenylchlor-formiat eller phosgen, eller b) at en forbindelse med formlen: ?H20r2° r17 CH2OR20 R19°- J^nK19 X iT ij ck3 N S»-^ch3_ 19 20 hydrolyseres, idet R og R er ens eller forskellige og er hydrogen eller en syrelabil beskyttende gruppe, 19 20 eller R og R tilsammen repræsenterer en gruppe med formlen: R4 4 5 hvor R og R er ens eller forskellige og repræsenterer hydrogen, C, ,alkyl eller phenyl, og R^ repræsenterer j 8 28 =0 eller =N-R , hvor R er hydrogen, phenyl eller C, , 17 o 19 20 alkyl, idet, hvis R er =0, sa er R og R ikke begge hydrogen, eller
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36877473A | 1973-06-15 | 1973-06-15 | |
| US36877473 | 1973-06-15 | ||
| US47023174 | 1974-05-16 | ||
| US05/470,231 US3971797A (en) | 1973-06-15 | 1974-05-16 | S,S'-bis(pyridylmethyl)-carbonodithioates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK303274A DK303274A (da) | 1975-02-10 |
| DK148595B true DK148595B (da) | 1985-08-12 |
| DK148595C DK148595C (da) | 1986-01-27 |
Family
ID=27004328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK303274A DK148595C (da) | 1973-06-15 | 1974-06-06 | Analogifremgangsmaade til fremstilling af s,s'-bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)carbonodithioat eller pharmaceutiskacceptable salte deraf |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US3971797A (da) |
| JP (3) | JPS5032180A (da) |
| AR (1) | AR203749A1 (da) |
| BG (1) | BG24408A3 (da) |
| CA (1) | CA1037956A (da) |
| CH (4) | CH613951A5 (da) |
| DD (1) | DD113001A5 (da) |
| DE (2) | DE2428294A1 (da) |
| DK (1) | DK148595C (da) |
| ES (1) | ES427277A1 (da) |
| FI (1) | FI58775C (da) |
| FR (2) | FR2233057B1 (da) |
| GB (2) | GB1466386A (da) |
| IE (1) | IE39467B1 (da) |
| IL (1) | IL44998A (da) |
| LU (1) | LU70342A1 (da) |
| NL (2) | NL185841C (da) |
| NO (1) | NO144149C (da) |
| PH (1) | PH10366A (da) |
| RO (2) | RO70852A (da) |
| SE (1) | SE411346B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4061759A (en) * | 1975-05-19 | 1977-12-06 | Merck & Co., Inc. | Ethenyl and ethynyl mercaptoalkyl pyridines |
| CH655110A5 (de) * | 1982-09-03 | 1986-03-27 | Otsuka Pharma Co Ltd | Carbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten. |
| US5595995A (en) * | 1992-05-15 | 1997-01-21 | British Technology Group Limited | Pyridyl-propan-2-yl esters of 1-adamantane carboxylates |
| GB2266887B (en) * | 1992-05-15 | 1996-04-17 | British Tech Group | Substituted pyridines,their preparation and pharmaceutical use |
| GB201718148D0 (en) * | 2017-11-02 | 2017-12-20 | Ipotts Ltd | Hair cutting comb |
| GB2603007B (en) * | 2021-01-26 | 2023-01-11 | Pickuls Gizmo Ltd | A hair cutting guide |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3515726A (en) * | 1968-10-16 | 1970-06-02 | Olin Mathieson | 2,2'-bis(pyridyl-n-oxide) dithiolcarbonates and trithiocarbonates |
-
1974
- 1974-05-16 US US05/470,231 patent/US3971797A/en not_active Expired - Lifetime
- 1974-06-03 FI FI1685/74A patent/FI58775C/fi active
- 1974-06-04 SE SE7407296A patent/SE411346B/xx not_active IP Right Cessation
- 1974-06-06 NL NLAANVRAGE7407616,A patent/NL185841C/xx not_active IP Right Cessation
- 1974-06-06 NO NO742042A patent/NO144149C/no unknown
- 1974-06-06 NL NL7407618A patent/NL7407618A/xx not_active Application Discontinuation
- 1974-06-06 DK DK303274A patent/DK148595C/da not_active IP Right Cessation
- 1974-06-10 PH PH15930A patent/PH10366A/en unknown
- 1974-06-10 IL IL44998A patent/IL44998A/en unknown
- 1974-06-10 CA CA202,346A patent/CA1037956A/en not_active Expired
- 1974-06-11 IE IE1219/74A patent/IE39467B1/xx unknown
- 1974-06-12 DE DE19742428294 patent/DE2428294A1/de not_active Ceased
- 1974-06-12 GB GB2617674A patent/GB1466386A/en not_active Expired
- 1974-06-12 DE DE2428409A patent/DE2428409C3/de not_active Expired
- 1974-06-12 GB GB2617874A patent/GB1466295A/en not_active Expired
- 1974-06-13 FR FR7420549A patent/FR2233057B1/fr not_active Expired
- 1974-06-13 CH CH812274A patent/CH613951A5/xx not_active IP Right Cessation
- 1974-06-13 FR FR7420548A patent/FR2233056B1/fr not_active Expired
- 1974-06-14 RO RO7490744A patent/RO70852A/ro unknown
- 1974-06-14 AR AR254190A patent/AR203749A1/es active
- 1974-06-14 CH CH821974A patent/CH610305A5/xx not_active IP Right Cessation
- 1974-06-14 BG BG026975A patent/BG24408A3/xx unknown
- 1974-06-14 DD DD179177A patent/DD113001A5/xx unknown
- 1974-06-14 ES ES427277A patent/ES427277A1/es not_active Expired
- 1974-06-14 RO RO7479181A patent/RO71434A/ro unknown
- 1974-06-15 JP JP49067657A patent/JPS5032180A/ja active Pending
- 1974-06-15 JP JP49067658A patent/JPS5032181A/ja active Pending
- 1974-06-17 LU LU70342A patent/LU70342A1/xx unknown
-
1978
- 1978-01-13 JP JP209778A patent/JPS5387363A/ja active Granted
- 1978-03-20 CH CH303278A patent/CH634302A5/de not_active IP Right Cessation
- 1978-09-18 CH CH972578A patent/CH618428A5/de not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA003275B1 (ru) | Ароматические амиды, способ их получения и их применение в качестве лекарственных средств | |
| AU653398B2 (en) | Substituted carboxylic acid derivatives | |
| WO2010083732A1 (zh) | N-乙酰神经氨酸类化合物、其药物组合物及其制备方法和用途 | |
| JPH03169860A (ja) | 置換n―ベンジルピペリジンアミド | |
| DK148595B (da) | Analogifremgangsmaade til fremstilling af s,s'-bis-(3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridylmethyl)carbonodithioat eller pharmaceutiskacceptable salte deraf | |
| EP0494850A2 (en) | Novel antiviral compounds | |
| JPH05271214A (ja) | ベンゾフラニル−およびチオフエニルメチルチオ−アルカンカルボン酸誘導体 | |
| AU628324B2 (en) | Compounds for inhibiting the biosynthesis of lipoxygenase -derived metabolites of arachidonic acid | |
| JP2001240581A (ja) | アミノベンズアミド誘導体およびその用途 | |
| US4539326A (en) | 5-Oxo-5H-(1)benzopyrano(2,3-b)pyridine derivatives, their production and use as anti-inflammatory agents | |
| CN102351854A (zh) | 氨基噻唑衍生物及制备方法和医药用途 | |
| CZ390392A3 (en) | Benzofuranyl- and thiophenylmethylthio alkanecarboxylic acid derivatives, process of their preparation and use | |
| CN112010819A (zh) | 一种含有苯甲酰胺的苯并六元杂环衍生物及其在抗肿瘤药物中的应用 | |
| WO2006101454A1 (en) | Benzothiophene derivatives: preparation and pharmaceutical applications | |
| CN104974108B (zh) | 一类2,2’‑串联双噻唑类化合物及其制备方法和用途 | |
| CN116891455A (zh) | 一种n-取代苯基-哒嗪酮-3-甲酰胺类化合物及其制备方法和应用及一种药物组合物 | |
| FI96417C (fi) | Menetelmä uusien terapeuttisesti käyttökelpoisten isokinoliinijohdannaisten valmistamiseksi | |
| JPH07252260A (ja) | 新規チエノチアジン誘導体、その製造方法及びその使用方法 | |
| US20120035217A1 (en) | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | |
| TW202342467A (zh) | 含氮雜環化合物的製備方法 | |
| CN1061646C (zh) | 取代苄脲衍生物和含有该衍生物的药物 | |
| JPS6165869A (ja) | キノリン−n−オキシド誘導体 | |
| DK164787B (da) | 3-substituerede pyrazolooe1,5-aaapyridinderivater, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat | |
| JP2001278872A (ja) | 新規アミノチアゾール誘導体 | |
| JPS61257981A (ja) | ジベンズ〔b,e〕オキセピン誘導体および抗アレルギ−剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PBP | Patent lapsed |